Last reviewed · How we verify
clopidogrel + aspirin OR prasugrel + aspirin
clopidogrel + aspirin OR prasugrel + aspirin is a Dual antiplatelet therapy (DAPT) Small molecule drug developed by Abbott Medical Devices. It is currently FDA-approved for Acute coronary syndrome (STEMI, NSTEMI), Prevention of stent thrombosis after percutaneous coronary intervention, Secondary prevention of cardiovascular events in coronary artery disease. Also known as: Dual Antiplatelet Therapy.
This dual antiplatelet therapy combines two P2Y12 inhibitors (clopidogrel or prasugrel) with aspirin to prevent blood clots by blocking platelet aggregation through different pathways.
This dual antiplatelet therapy combines two P2Y12 inhibitors (clopidogrel or prasugrel) with aspirin to prevent blood clots by blocking platelet aggregation through different pathways. Used for Acute coronary syndrome (STEMI, NSTEMI), Prevention of stent thrombosis after percutaneous coronary intervention, Secondary prevention of cardiovascular events in coronary artery disease.
At a glance
| Generic name | clopidogrel + aspirin OR prasugrel + aspirin |
|---|---|
| Also known as | Dual Antiplatelet Therapy |
| Sponsor | Abbott Medical Devices |
| Drug class | Dual antiplatelet therapy (DAPT) |
| Target | P2Y12 receptor (clopidogrel/prasugrel) and cyclooxygenase (aspirin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel and prasugrel are thienopyridine P2Y12 receptor antagonists that irreversibly inhibit ADP-mediated platelet activation, while aspirin irreversibly inhibits cyclooxygenase to block thromboxane A2 production. Together, they provide synergistic antiplatelet effects by targeting complementary pathways of platelet aggregation, reducing thrombotic events in acute coronary syndromes and after percutaneous coronary intervention.
Approved indications
- Acute coronary syndrome (STEMI, NSTEMI)
- Prevention of stent thrombosis after percutaneous coronary intervention
- Secondary prevention of cardiovascular events in coronary artery disease
Common side effects
- Bleeding (major and minor)
- Dyspepsia
- Rash
- Thrombotic thrombocytopenic purpura (TTP)
- Neutropenia
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clopidogrel + aspirin OR prasugrel + aspirin CI brief — competitive landscape report
- clopidogrel + aspirin OR prasugrel + aspirin updates RSS · CI watch RSS
- Abbott Medical Devices portfolio CI
Frequently asked questions about clopidogrel + aspirin OR prasugrel + aspirin
What is clopidogrel + aspirin OR prasugrel + aspirin?
How does clopidogrel + aspirin OR prasugrel + aspirin work?
What is clopidogrel + aspirin OR prasugrel + aspirin used for?
Who makes clopidogrel + aspirin OR prasugrel + aspirin?
Is clopidogrel + aspirin OR prasugrel + aspirin also known as anything else?
What drug class is clopidogrel + aspirin OR prasugrel + aspirin in?
What development phase is clopidogrel + aspirin OR prasugrel + aspirin in?
What are the side effects of clopidogrel + aspirin OR prasugrel + aspirin?
What does clopidogrel + aspirin OR prasugrel + aspirin target?
Related
- Drug class: All Dual antiplatelet therapy (DAPT) drugs
- Target: All drugs targeting P2Y12 receptor (clopidogrel/prasugrel) and cyclooxygenase (aspirin)
- Manufacturer: Abbott Medical Devices — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome (STEMI, NSTEMI)
- Indication: Drugs for Prevention of stent thrombosis after percutaneous coronary intervention
- Indication: Drugs for Secondary prevention of cardiovascular events in coronary artery disease
- Also known as: Dual Antiplatelet Therapy
- Compare: clopidogrel + aspirin OR prasugrel + aspirin vs similar drugs
- Pricing: clopidogrel + aspirin OR prasugrel + aspirin cost, discount & access